STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXEO
  4. [Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

LXEO insider: holdings 242,118 incl. 131,092 RSUs

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) reported insider activity by its Chief Executive Officer and Director. On 10/15/2025, the reporting person acquired 33,000 shares of Common Stock at $0 upon RSU release. On 10/17/2025, shares were sold to cover taxes in open market transactions: 12,985 shares at a weighted average price of $8.935 and 148 shares at a weighted average price of $9.561. Following these transactions, beneficial ownership stands at 242,118 shares, which includes 131,092 RSUs, held directly.

Positive

  • None.

Negative

  • None.
Insider Townsend Richard Nolan
Role Chief Executive Officer
Sold 13,133 shs ($117K)
Type Security Shares Price Value
Sale Common Stock 12,985 $8.935 $116K
Sale Common Stock 148 $9.561 $1K
Grant/Award Common Stock 33,000 $0.00 --
Holdings After Transaction: Common Stock — 242,266 shares (Direct)
Footnotes (1)
  1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 131,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Townsend Richard Nolan
(Last) (First) (Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 A 33,000 A $0 255,251 D
Common Stock 10/17/2025 S(1) 12,985 D $8.935(2) 242,266 D
Common Stock 10/17/2025 S(1) 148 D $9.561(3) 242,118(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").
2. This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. Includes 131,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
/s/ Youjin Choi, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did LXEO disclose in this Form 4?

The CEO/Director reported a 33,000-share acquisition at $0 from RSU release on 10/15/2025 and tax-related sales on 10/17/2025.

How many shares were sold and at what prices?

12,985 shares at a weighted average price of $8.935 and 148 shares at a weighted average price of $9.561.

What is the executive’s current beneficial ownership in LXEO?

242,118 shares held directly, including 131,092 RSUs.

Why were the LXEO shares sold on 10/17/2025?

The filing states the sales were to cover tax obligations from the RSU release.

What is the executive’s relationship to Lexeo Therapeutics (LXEO)?

The reporting person is both a Director and the Chief Executive Officer.

Were the sale prices single trades or averages?

They were weighted average prices from multiple trades within stated price ranges.